Grifols (GRFS) Stock Forecast & Price Target

$8.36 -0.24 (-2.79%)

(As of 12:50 PM ET)

Grifols - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 3 Analyst Ratings

Sell
1

Hold
1

Buy
1

Based on 3 Wall Street analysts who have issued ratings for Grifols in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, 1 has given a hold rating, and 1 has given a strong buy rating for GRFS.

Consensus Price Target

$10.50
25.60% Upside

According to the 3 analysts' twelve-month price targets for Grifols, the average price target is $10.50. The highest price target for GRFS is $10.50, while the lowest price target for GRFS is $10.50. The average price target represents a forecasted upside of 25.60% from the current price of $8.36.

Get the Latest News and Ratings for GRFS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Grifols and its competitors.

GRFS Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.50	$10.50	$10.50	N/A
Forecasted Upside	25.60% Upside	19.05% Upside	22.38% Upside	N/A
Consensus Rating	Hold	Reduce	Reduce	Hold

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

GRFS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GRFS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Grifols Stock vs. The Competition

Type	Grifols	Medical Companies	S&P 500
Consensus Rating Score	2.33	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	26.51% Upside	26,931.27% Upside	9.84% Upside
News Sentiment Rating	Neutral News See Recent GRFS News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/29/2024	Berenberg Bank 2 of 5 stars	T. Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/12/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Downgrade	Hold ➝ Sell
12/5/2023	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Neutral ➝ Neutral	$10.00 ➝ $10.50	+6.82%
8/29/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight
2/16/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight
2/6/2023	AlphaValue Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Buy
1/18/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
11/25/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:09 PM ET.

GRFS Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Grifols is $10.50, with a high forecast of $10.50 and a low forecast of $10.50.
: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There is currently 1 sell rating, 1 hold rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GRFS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRFS, but not buy additional shares or sell existing shares.
: According to analysts, Grifols's stock has a predicted upside of 25.60% based on their 12-month stock forecasts.
: Over the previous 90 days, Grifols's stock had 1 upgrade by analysts.
: Grifols has been rated by research analysts at Berenberg Bank in the past 90 days.
: Analysts like Grifols less than other "medical" companies. The consensus rating for Grifols is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GRFS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NASDAQ:GRFS) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grifols (GRFS) Stock Forecast & Price Target